# US 2008/0306133 A1 · Intranasal administration of asenapine and pharmaceutical compositions therefor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0306133 A1
- Document ID: US20080306133A1
- Status: Published application
- Kind: A1
- Application number: 12/133,106
- Filed: 2008-06-04
- Published: 2008-12-11
- Earliest claimed: 2007-06-05
- Inventors: Josephine Elisabeth Maria van der Sterren; Dennie J.M. van den Heuvel
- Web page: https://patentgrep.com/patent/US20080306133A1

## CPC

- A61K 9/0043: {Nose}
- A61K 31/407: condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Asenapine or a pharmaceutically acceptable salt thereof can be administered intranasally, typically via an intranasal dosage formulation having a water-containing liquid carrier.

## Claims

### Claim 1

An intranasal dosage formulation, which comprises:
asenapine or a pharmaceutically acceptable salt thereof and a water-containing liquid carrier, wherein the formulation is adapted for intranasal administration.

### Claim 2 (depends on 1)

The dosage formulation according to claim 1, wherein said water-containing liquid carrier comprises water and a polyol.

### Claim 3 (depends on 2)

The dosage formulation according to claim 2, wherein said polyol is polyethylene glycol or propylene glycol.

### Claim 4 (depends on 3)

The dosage formulation according to claim 3, wherein said water and said polyol are present in a volume ratio within the range of 20:80 to 80:20.

### Claim 5 (depends on 1)

The dosage formulation according to claim 1, wherein said formulation contains asenapine or a pharmaceutically acceptable salt thereof in a concentration within the range of 5 to 100 mg/ml.

### Claim 6 (depends on 1)

The dosage formulation according to claim 1, which further comprises a bacteriostatic agent.

### Claim 7 (depends on 1)

The dosage formulation according to claim 1, which further comprises a buffering agent.

### Claim 8 (depends on 1)

The dosage formulation according to claim 1, which further comprises a permeation enhancing agent selected from the group consisting of:
(a) an absorption enhancing agent;
(b) an aggregation inhibitory agent;
(c) a degradative enzyme inhibitory agent;
(d) a mucolytic or mucus clearing agent;
(e) a ciliostatic agent;
(f) a modulatory agent of epithelial junction physiology;
(g) a vasodilator agent; and
(h) a complex-forming species.

### Claim 9 (depends on 8)

The dosage formulation according to claim 8, wherein said permeation enhancing agent is selected from the group consisting of a surfactant, a bile salt, a phospholipid additive, a mixed micelle, a liposome, an alcohol, an enamine, a nitric oxide donor compound, a salicylic acid derivative, a glycerol ester of acetoacetic acid, a cyclodextrin, a cyclodextrin derivative, a C1-C12 fatty acid, an amino acid or salt thereof, a complexing agent, a trypsin inhibitor, a sugar, and combinations thereof.

### Claim 10 (depends on 8)

The dosage formulation according to claim 8, wherein said permeation enhancing agent is selected from the group consisting of an N-acetylamino acid or salt thereof, NaCl, KCl, amastatin, sodium glycocholate, methionine, cysteine, threonine, benzalkonium chloride, EDTA, citric acid, a poloxamer, a polyol, a salicylate, arginine, polyarginine, and combinations thereof.

### Claim 11 (depends on 1)

The dosage formulation according to claim 1, wherein the formulation has a pH in a range of 4.0 to 6.0.

### Claim 12 (depends on 1)

The intranasal dosage formulation of claim 1, wherein the pharmaceutically acceptable salt of asenapine is asenapine maleate.

### Claim 13

An intranasal dosage formulation, which comprises:
asenapine or a pharmaceutically acceptable salt thereof in a concentration of 10 to 100 mg/ml;
a liquid carrier comprising water and a polyol;
an isotonizing agent;
optionally a bacteriostatic agent; and
optionally a thickener and/or a humectant.

### Claim 14 (depends on 13)

The dosage formulation according to claim 13, wherein said asenapine or pharmaceutically acceptable salt thereof is asenapine maleate.

### Claim 15 (depends on 14)

The dosage formulation according to claim 14 wherein the polyol is polyethylene glycol, propylene glycol, or combinations thereof.

### Claim 16 (depends on 15)

The dosage formulation according to claim 15, wherein said asenapine maleate is contained in an amount within the range of 20 to 100 mg/ml.

### Claim 17

A method, which comprises administering via intranasal exposure an effective amount of asenapine or a pharmaceutically acceptable salt thereof to a patient in need thereof.

### Claim 18 (depends on 18)

The method according to claim 18, wherein said patient is suffering from schizophrenia and said amount of asenapine is an anti-schizophrenia effective amount.

### Claim 19 (depends on 1)

A method for treating asenapine-treatable conditions, which comprises intranasally administering an effective amount of the intranasal dosage formulation according to claim 1, to a patient suffering from an asenapine-treatable condition.

### Claim 20 (depends on 19)

The method according to claim 19, wherein said patient is suffering from schizophrenia and said amount administered is an anti-schizophrenia effective amount of asenapine.
